english.prescrire.org > Prescrire International > N°114 - March 2011

n°114

March 2011

Issue Contents
Editorial

Free  Decisions that put patients at risk

p.60
Health professionals cannot put their trust in regulators

Marketing Authorisations


Imatinib and inoperable or metastatic gastrointestinal stromal tumours (A Second Look)

p.61-63
Longer follow-up confirms the overall survival benefit

Pazopanib (New Drug)

p.64-66
Kidney cancer: many risks, but is there a benefit for patients?

INN common-stem: -pitant

p.66

Amlodipine + valsartan + hydrochlorothiazide (New Combination)

p.67
A 3-drug fixed-dose combination for hypertension: too many drawbacks

Botulinum toxin type A in children (New Indication for limb spasticity)

p.68
Clinical impact unclear

Adverse Effects


Free  31st French Pharmacovigilance Meeting. Inhibition of lactation: risks associated with dopamine agonists

p.69
Potentially severe reactions

31st French Pharmacovigilance Meeting. Advantages of adverse-effect reporting by patients

p.70
A useful complement to reports by health professionals

31st French Pharmacovigilance Meeting. Colchicine: caution!

p.70
4 risk factors

31st French Pharmacovigilance Meeting. Methods for improving the reporting of adverse effects

p.71
Several convincing experiments

Reviews


Preventing neonatal Group B streptococcal infection

p.72-77
Intrapartum antibiotic prophylaxis in some high-risk situations

Prescrire's advice : Screening for Group B streptococci: bacterial culture in late pregnancy

p.76

Type 2 diabetes: targeting blood pressure below 140/80 mmHg

p.77
Targeting below 120 mmHg is no better

Informing patients of the long-term effects of treatments for localised prostate cancer

p.78
Quality of life is key

Outlook


Free  2010 Prescrire Awards

p.79-82

Free  2010 Prescrire Drug Awards

p.80

Free  2010 Prescrire Packaging Awards

p.81

Free  2010 Prescrire Information Awards

p.82

Free  Prescrire's at-a-glance drug rating system

p.84

Masthead


Free  Masthead

p.58

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe